

FoI request re: atopic dermatitis treatments
Ref: 20-EB-0109

Thank you for your request for information relating to atopic dermatitis treatments.

This was received on 03 August 2020 and has been dealt with under the terms of the Freedom of Information Act 2000.

Please find our responses below:

Request 1:

How many patients were treated within your Trust with the following drugs within the specified time periods?

Drug	Number of patients treated between 01 February 2017 and 31 July 2018	Number of patients treated between 01 August 2018 and 31 January 2020
Apremilast	8	0
Adalimumab	170	283
Dupilumab	0	≤5
Etanercept	210	130
Infliximab	125	129
Secukinumab	19	56
Ustekinumab	53	95

Please note that the trust's policy is not to provide patient or staff numbers, where the response is less than or equal to five (≤5) as it would potentially allow identification of the individual patient/staff and would therefore be personal data. The trust considers that release of that information would breach GDPR/DPA18 principles on the grounds that it would not be fair in all the circumstances. This information is therefore exempt under section 40 of the FOI Act 2000.

Request 2:

How many patients were treated within your Trust for atopic dermatitis within the specified time periods?

We are unable to provide you with this information as there is no diagnosis coding where this treatment would usually be carried out.

Number of patients treated for atopic	Number of patients treated for atopic
---------------------------------------	---------------------------------------

Whittington Health NHS Trust

Interim Chair: Anu Singh Chief Executive: Siobhan Harrington

dermatitis between 01 February 2017 and 31 July 2018	dermatitis between 01 August 2018 and 31 January 2020

Request 3:

How many patients were treated within your Trust with the following drugs for atopic dermatitis within the specified time periods?

We do not hold this information as indication is not mapped to drug on our system.

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast		
Adalimumab		
Dupilumab		
Etanercept		
Infliximab		
Secukinumab		
Ustekinumab		

Request 4:

Please specify how patients treated with the following drugs are coded (OPCS code) within your trust:

We do not hold this information as indication is not mapped to drug on our system.

Drug	OPCS code (e.g. X385 subcutaneous immunotherapy)
Apremilast	
Adalimumab	
Dupilumab	
Etanercept	
Infliximab	

Whittington Health NHS Trust

Interim Chair: Anu Singh Chief Executive: Siobhan Harrington

Secukinumab	
Ustekinumab	

Request 5:

Please provide the number of patients treated in the homecare setting for atopic dermatitis within the specified time periods:

We do not keep Homecare data against indication.

Number of patients treated in the homecare setting for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated in the homecare setting for atopic dermatitis between 01 August 2018 and 31 January 2020

Request 6:

How many of your Trust's homecare patients were treated with the following drugs for atopic dermatitis within the specified time periods?

We do not hold this information as indication is not mapped to drug on our system.

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast		
Adalimumab		
Dupilumab		
Etanercept		
Infliximab		
Secukinumab		
Ustekinumab		

Whittington Health NHS Trust

Interim Chair: Anu Singh Chief Executive: Siobhan Harrington